Meiji Yasuda Life Insurance Co decreased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 9.5% during the 1st quarter, HoldingsChannel reports. The fund owned 4,526 shares of the life sciences company’s stock after selling 474 shares during the period. Meiji Yasuda Life Insurance Co’s holdings in Illumina were worth $1,406,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Andra AP fonden purchased a new stake in Illumina during the 1st quarter worth about $5,126,000. Williams Jones & Associates LLC increased its holdings in shares of Illumina by 34.2% in the 1st quarter. Williams Jones & Associates LLC now owns 1,751 shares of the life sciences company’s stock valued at $544,000 after acquiring an additional 446 shares during the last quarter. American Capital Management Inc. increased its holdings in shares of Illumina by 0.4% in the 1st quarter. American Capital Management Inc. now owns 256,360 shares of the life sciences company’s stock valued at $79,648,000 after acquiring an additional 937 shares during the last quarter. Tyers Asset Management LLC increased its holdings in shares of Illumina by 10.9% in the 1st quarter. Tyers Asset Management LLC now owns 9,152 shares of the life sciences company’s stock valued at $2,843,000 after acquiring an additional 896 shares during the last quarter. Finally, TCW Group Inc. increased its holdings in shares of Illumina by 7.5% in the 1st quarter. TCW Group Inc. now owns 403,564 shares of the life sciences company’s stock valued at $125,383,000 after acquiring an additional 28,188 shares during the last quarter. 89.73% of the stock is currently owned by hedge funds and other institutional investors.
In related news, Director Robert S. Epstein sold 1,000 shares of the company’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $314.45, for a total value of $314,450.00. Following the completion of the sale, the director now directly owns 4,256 shares of the company’s stock, valued at approximately $1,338,299.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Jay T. Flatley sold 3,300 shares of the company’s stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $306.93, for a total value of $1,012,869.00. Following the completion of the sale, the director now directly owns 338,268 shares of the company’s stock, valued at $103,824,597.24. The disclosure for this sale can be found here. Over the last three months, insiders sold 45,731 shares of company stock valued at $14,221,546. Insiders own 0.38% of the company’s stock.
Shares of NASDAQ ILMN traded up $1.02 during trading hours on Wednesday, reaching $336.91. The stock had a trading volume of 10,995 shares, compared to its average volume of 961,284. The stock has a market cap of $49.30 billion, a PE ratio of 58.84, a price-to-earnings-growth ratio of 2.34 and a beta of 1.06. The company has a quick ratio of 3.33, a current ratio of 3.66 and a debt-to-equity ratio of 0.27. Illumina, Inc. has a fifty-two week low of $268.62 and a fifty-two week high of $372.61.
Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, April 25th. The life sciences company reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.26. The firm had revenue of $846.00 million during the quarter, compared to analysts’ expectations of $838.70 million. Illumina had a return on equity of 23.49% and a net margin of 25.06%. The business’s revenue was up 8.2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.45 EPS. Sell-side analysts anticipate that Illumina, Inc. will post 6.68 earnings per share for the current year.
A number of research analysts have recently commented on the company. BidaskClub upgraded Illumina from a “hold” rating to a “buy” rating in a report on Tuesday. Canaccord Genuity reiterated a “buy” rating and issued a $360.00 price objective (up previously from $350.00) on shares of Illumina in a report on Monday. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $355.00 price objective on the stock in a report on Tuesday, April 2nd. OTR Global downgraded Illumina to a “positive” rating in a report on Tuesday, April 2nd. Finally, Wolfe Research assumed coverage on Illumina in a report on Thursday, May 30th. They issued an “outperform” rating on the stock. Two analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $354.35.
ILLEGAL ACTIVITY WARNING: This piece of content was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2019/06/12/meiji-yasuda-life-insurance-co-decreases-position-in-illumina-inc-nasdaqilmn.html.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Recommended Story: Portfolio Manager
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.